Nanosphere, Inc., (NASDAQ:
NSPH), announced today that William H. Cork, the company's vice president
for research and development and chief technology officer, was inducted into
the American Institute of Medical and Biological Engineering's (AIMBE) prestigious
College of Fellows at the Institute's annual event at the National Academy of
Sciences in Washington, D.C. on February 12, 2009.
Mr. Cork was one of 96 newly elected Fellows of AIMBE, who joined the other
900 distinguished scientists and engineers as leaders in the development of
biomedical devices and processes, treatment of diseases, and public policy related
to all aspects of medical and biological engineering." In presenting the
award to Mr. Cork, Jennifer Ayers, AIMBE's Executive Director, noted his accomplishments
"for the development of highly sensitive molecular diagnostic systems based
on nanotechnology as well as important blood separation technologies."
As head of research and development at Nanosphere, Mr. Cork led the company's
effort to develop the The Verigene® System, an FDA-approved molecular diagnostics
workstation that utilizes patented gold nanoparticle technology to detect nucleic
acid and protein targets of interest for a variety of applications. Under Mr.
Cork's leadership, Nanosphere also received the FDA's first clearance of a test
to determine an individual's ability to metabolize the anti-coagulant medication
warfarin, information critical to determining safe and appropriate dosing, on
the nanotechnology based Verigene® System.
Commenting on Mr. Cork's induction into the AIMBE College of Fellows, William
P. Moffitt, Nanosphere's president and chief executive officer, said, "We
are extremely proud of Bill Cork and the cutting-edge research that he and his
team have done in the development of our Verigene system. It is not surprising
to us that his work has now been recognized by the American Institute of Medical
and Biological Engineers, and he takes his rightful place among the leading
scientists and engineers who have made their mark on the world of biomedical
Mr. Cork joined Nanosphere as vice president of research and development and
chief technology officer at the inception of the company in 2000. Previously,
he had developed a blood separation system at Baxter Healthcare, and holds numerous